Bayer's sturdy pharma growth highlights Monsanto risks by Tracy Staton Wednesday, February 22, 2017 Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer now, its future pharma growth could be in jeopardy.
